Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
|Videos|January 27, 2014
Aspirin and Targeting COX-2 in Colorectal Cancer
Author(s)Charles S. Fuchs, MD, MPH
Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, on the use of aspirin and targeting COX-2 in colorectal cancer.
Advertisement
Clinical Pearls
Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, on the use of aspirin and targeting COX-2 in colorectal cancer.
- Level 1 evidence exists for aspirin as a preventative agent against colorectal polyps or cancer
- In several observational studies, patients who have started chemotherapy for CRC and reported aspirin use had significant improvement in cancer-free survival
- It is widely believed that one target for aspirin is cyclooxygenase-2 (COX-2), a marker that affects an increased proliferation in cancer cells
- Aspirin has demonstrated efficacy in patients with COX-2-overexpressing colon cancer
- There is a need for randomized trials in this space like CALGB 80702, in which patients who have been resected for stage 3 colon cancer will receive chemotherapy and will be randomized to a COX-2 inhibitor (not aspirin)
Advertisement
Related to this article
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
3
Denosumab Biosimilar Approved For Existing Oncology Indications
4
CEPHEUS and Frontline Treatment in Newly Diagnosed Multiple Myeloma
5